share_log

醫思健康：2024/25 半年度業績報告

EC HEALTHCARE: INTERIM REPORT 2024/25

HKEX ·  Dec 20 16:57

Summary by Moomoo AI

醫思健康公佈截至2024年9月30日止六個月中期業績。期內收入下降2.8%至20.63億港元，主要受宏觀經濟環境影響。淨利潤大幅增長88.1%至4030萬港元，每股基本盈利1.2港仙。醫療服務收入下降3.7%至12.64億港元，美學醫療及美容養生服務收入下降5.4%至6.30億港元，獸醫及其他服務收入增長18.9%至1.69億港元。集團積極應對市場挑戰，採取多項措施提升營運效率。包括優化新設服務點營運、總部成本控制、利息開支管理等。同時加強B2B、B2I及B2G業務機會，提升服務網絡互聯互通。集團亦審慎管理營運資金，實施重大成本重組，包括減少員工、優化租賃等。展望未來，集團對香港醫療市場保持審慎樂觀。將聚焦三大領域實現利潤增長:業務發展、卓越營運及數字化轉型。集團將利用平台方法創造相關產品，提升人才生產力和資產利用率，並加強數字化能力。同時將繼續尋求戰略併購機會，優化資產組合，為股東創造長期價值。
醫思健康公佈截至2024年9月30日止六個月中期業績。期內收入下降2.8%至20.63億港元，主要受宏觀經濟環境影響。淨利潤大幅增長88.1%至4030萬港元，每股基本盈利1.2港仙。醫療服務收入下降3.7%至12.64億港元，美學醫療及美容養生服務收入下降5.4%至6.30億港元，獸醫及其他服務收入增長18.9%至1.69億港元。集團積極應對市場挑戰，採取多項措施提升營運效率。包括優化新設服務點營運、總部成本控制、利息開支管理等。同時加強B2B、B2I及B2G業務機會，提升服務網絡互聯互通。集團亦審慎管理營運資金，實施重大成本重組，包括減少員工、優化租賃等。展望未來，集團對香港醫療市場保持審慎樂觀。將聚焦三大領域實現利潤增長:業務發展、卓越營運及數字化轉型。集團將利用平台方法創造相關產品，提升人才生產力和資產利用率，並加強數字化能力。同時將繼續尋求戰略併購機會，優化資產組合，為股東創造長期價值。
EC HEALTHCARE announced its interim results for the six months ended September 30, 2024. Revenue decreased by 2.8% to 2.063 billion HKD, mainly due to the impact of the macroeconomic environment. Net profit surged by 88.1% to 40.3 million HKD, with basic earnings per share at 1.2 HKD cents. Revenue from Veterinary Services fell by 3.7% to 1.264 billion HKD, while revenue from aesthetic medical and beauty wellness services decreased by 5.4% to 0.63 billion HKD. Revenue from veterinary and Other services rose by 18.9% to 0.169 billion HKD.The group actively addresses market challenges by implementing various measures to enhance operational efficiency. This includes optimizing the operation of newly established service points, controlling headquarters costs, and managing interest expenses. At the same time, it strengthens B2B, B2I, and B2G business opportunities, enhancing the connectivity of...Show More
EC HEALTHCARE announced its interim results for the six months ended September 30, 2024. Revenue decreased by 2.8% to 2.063 billion HKD, mainly due to the impact of the macroeconomic environment. Net profit surged by 88.1% to 40.3 million HKD, with basic earnings per share at 1.2 HKD cents. Revenue from Veterinary Services fell by 3.7% to 1.264 billion HKD, while revenue from aesthetic medical and beauty wellness services decreased by 5.4% to 0.63 billion HKD. Revenue from veterinary and Other services rose by 18.9% to 0.169 billion HKD.The group actively addresses market challenges by implementing various measures to enhance operational efficiency. This includes optimizing the operation of newly established service points, controlling headquarters costs, and managing interest expenses. At the same time, it strengthens B2B, B2I, and B2G business opportunities, enhancing the connectivity of the service network. The group also prudently manages operating capital, implementing significant cost restructuring, including reducing staff and optimizing leases.Looking ahead, the group remains cautiously optimistic about the Hong Kong medical market. It will focus on three key areas to achieve profit growth: business development, operational excellence, and digital transformation. The group will utilize a platform approach to create relevant products, enhance talent productivity and Asset utilization, and strengthen digital capabilities. Additionally, it will continue to seek strategic acquisition opportunities to optimize the asset portfolio and create long-term value for Shareholders.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated